VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results…

Source

Previous articleEntheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today
Next articleEntheon Biomedical Corp. Files Preliminary Shelf Prospectus